DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $180,000 | -10.0% | 601 | -1.2% | 0.02% | -4.2% |
| Q4 2021 | $200,000 | +11.7% | 608 | +3.4% | 0.02% | +4.3% |
| Q3 2021 | $179,000 | +14.7% | 588 | +1.4% | 0.02% | +15.0% |
| Q2 2021 | $156,000 | +23.8% | 580 | +3.6% | 0.02% | +17.6% |
| Q1 2021 | $126,000 | -39.4% | 560 | -40.3% | 0.02% | -43.3% |
| Q4 2020 | $208,000 | +12.4% | 938 | +9.1% | 0.03% | +7.1% |
| Q3 2020 | $185,000 | +12.8% | 860 | -7.5% | 0.03% | +7.7% |
| Q2 2020 | $164,000 | +15.5% | 930 | -9.6% | 0.03% | 0.0% |
| Q1 2020 | $142,000 | -4.7% | 1,029 | +6.3% | 0.03% | +13.0% |
| Q4 2019 | $149,000 | -20.7% | 968 | -25.7% | 0.02% | -25.8% |
| Q3 2019 | $188,000 | +1.1% | 1,302 | 0.0% | 0.03% | -3.1% |
| Q2 2019 | $186,000 | +257.7% | 1,302 | +231.3% | 0.03% | +220.0% |
| Q1 2019 | $52,000 | +36.8% | 393 | +5.6% | 0.01% | +25.0% |
| Q4 2018 | $38,000 | -5.0% | 372 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $40,000 | -20.0% | 372 | -27.1% | 0.01% | -27.3% |
| Q2 2018 | $50,000 | -47.4% | 510 | -47.5% | 0.01% | -50.0% |
| Q1 2018 | $95,000 | +171.4% | 972 | +161.3% | 0.02% | +120.0% |
| Q4 2017 | $35,000 | +20.7% | 372 | +8.8% | 0.01% | +11.1% |
| Q3 2017 | $29,000 | 0.0% | 342 | +0.6% | 0.01% | 0.0% |
| Q2 2017 | $29,000 | +93.3% | 340 | +71.7% | 0.01% | +80.0% |
| Q4 2016 | $15,000 | -6.2% | 198 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $16,000 | -38.5% | 198 | -22.7% | 0.01% | -37.5% |
| Q2 2016 | $26,000 | +8.3% | 256 | 0.0% | 0.01% | +14.3% |
| Q1 2016 | $24,000 | -17.2% | 256 | -19.0% | 0.01% | -22.2% |
| Q4 2015 | $29,000 | +31.8% | 316 | +22.5% | 0.01% | +12.5% |
| Q3 2015 | $22,000 | 0.0% | 258 | 0.0% | 0.01% | -11.1% |
| Q2 2015 | $22,000 | 0.0% | 258 | 0.0% | 0.01% | 0.0% |
| Q1 2015 | $22,000 | 0.0% | 258 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $22,000 | +46.7% | 258 | +30.3% | 0.01% | +28.6% |
| Q3 2014 | $15,000 | 0.0% | 198 | 0.0% | 0.01% | 0.0% |
| Q2 2014 | $15,000 | 0.0% | 198 | 0.0% | 0.01% | -22.2% |
| Q1 2014 | $15,000 | +87.5% | 198 | +80.0% | 0.01% | +50.0% |
| Q4 2013 | $8,000 | -11.1% | 110 | -21.4% | 0.01% | -40.0% |
| Q2 2013 | $9,000 | – | 140 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |